Teclistamab shows promising results in frontline multiple myeloma treatment, achieving high MRD negativity rates, but safety concerns remain.
Marc Raab, MD
Advertisement
Articles by Marc Raab, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
ACIP Meeting: COVID-19 Vaccines to be Administered Through Shared Clinical Decision-Making
2
IMS 2025: Advancing Immunotherapy with Costimulatory Bispecific Antibodies in Multiple Myeloma
3
IMS 2025: Daratumumab Plus Lenalidomide Improves Outcomes in Post-Transplant Maintenance for Myeloma
4
Linvoseltamab Plus Carfilzomib Yields Deep, Durable Responses in Patients With RRMM
5
